Shire Continues to Deliver Excellent Growth From Cor...(his rolehe had responsibility for GSK's ...),Health

The Shire Board also announces that Mr David Mott will be stepping down from the Shire Board on the expiry of his term of office on October 30, 2009.

Matt Emmens, Chairman of Shire commented;

"We are delighted to welcome David Stout to the Shire Board. He brings with him extensive international experience in the pharmaceutical industry, which we believe will be of great value to Shire as it continues its growth trajectory and becomes a more global company.

We would also like to thank David Mott for his valuable contribution to the Shire Board over the last few years."

Dial in details for the live conference call for investors 14:00 GMT/ 10:00 ET on October 30, 2009:

    UK dial in: 0800-077-8492 or 0-1296-311-600
    US dial in: 1-866-804-8688 or 1-718-354-1175
    International dial in: +44(0)1296-311-600

    Password/Conf ID: 891 799#

    Live Webcast: http://www.shire.com/shire/InvestorRelations/index.jsp?tn=2
    OVERVIEW OF FINANCIAL RESULTS
    1. Introduction
    Summary of Q3 2009

Revenues from continuing operations for the three months to September 30, 2009 decreased by 14% to $667.0 million (2008: $778.6 million), due to the decline in branded ADDERALL XR product sales in Q3 2009 following the launch of an authorized generic version by Teva in April 2009. However, core product sales increased by 20% to $531.6 million (2008: $443.8 million).

Non GAAP operating income for the three months to September 30, 2009 decreased by 52% to $133.6 million (
'/>"/>